Progress in building clinically relevant patient‐derived tumor xenograft models for cancer research
Weijing Wang,Yongshu Li,Kaida Lin,Xiaokang Wang,Yanyang Tu,Zhenjian Zhuo
DOI: https://doi.org/10.1002/ame2.12349
2023-09-09
Animal Models and Experimental Medicine
Abstract:Patient‐derived tumor xenografts (PDX) have evolved since 1953, involving tumor implantation into immunodeficient mice. Uncertain engraftment rates obscure benefits like retained tumor characteristics and enhanced drug sensitivity. Patient‐derived orthotopic xenografts (PDOX), emerging in 1982, enhance drug assessment and metastatic capabilities. Humanized mice (1988) involve transplanting immune components, resembling human tumor microenvironments. Zebrafish PDX (2005) offer quick modeling, drug testing, and live imaging, aiding metastasis and molecular mechanism studies. Patient‐derived tumor xenograft (PDX) models, a method involving the surgical extraction of tumor tissues from cancer patients and subsequent transplantation into immunodeficient mice, have emerged as a pivotal approach in translational research, particularly in advancing precision medicine. As the first stage of PDX development, the patient‐derived orthotopic xenograft (PDOX) models implant tumor tissue in mice in the corresponding anatomical locations of the patient. The PDOX models have several advantages, including high fidelity to the original tumor, heightened drug sensitivity, and an elevated rate of successful transplantation. However, the PDOX models present significant challenges, requiring advanced surgical techniques and resource‐intensive imaging technologies, which limit its application. And then, the humanized mouse models, as well as the zebrafish models, were developed. Humanized mouse models contain a human immune environment resembling the tumor and immune system interplay. The humanized mouse models are a hot topic in PDX model research. Regarding zebrafish patient‐derived tumor xenografts (zPDX) and patient‐derived organoids (PDO) as promising models for studying cancer and drug discovery, zPDX models are used to transplant tumors into zebrafish as novel personalized medical animal models with the advantage of reducing patient waiting time. PDO models provide a cost‐effective approach for drug testing that replicates the in vivo environment and preserves important tumor‐related information for patients. The present review highlights the functional characteristics of each new phase of PDX and provides insights into the challenges and prospective developments in this rapidly evolving field.